Зарегистрировано 22. november 2022, основной вид деятельности: Прочая профессиональная, научная и техническая деятельность, не включённая в другие группировки. Основное место деятельности — Kesklinna linnaosa, Tallinn, Harju maakond.
| Год | Выручка | Прибыль | Собственный капитал | Активы | Сотрудников | ||
|---|---|---|---|---|---|---|---|
| 2024 |
| Год | Оборот (г) | Государственные налоги | Налоги на рабочую силу | Сотрудников (Q4) |
|---|---|---|---|---|
| 2026I кв. | 0 € | – | – | – |
| 2025 | 0 € | 2095 € | 121 € | – |
| 2024 | 0 € | 725 € | 729 € | 1 |
| 24 000 € |
| 15 854 € |
| 34k € |
| 34k € |
| 1 |
| 18.11.2025 |
| 2023 | 0 € | −1451 € | -1k € | 114 € | 0 | 17.05.2024 |
| Год | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Оборот 2026 | 0 € | – | – | – |
| Государственные налоги 2026 | – | – | – | – |
| Налоги на рабочую силу 2026 | – | – | – | – |
| Сотрудников 2026 | – | – | – | – |
| Оборот 2025 | 0 € | 0 € | 0 € | 0 € |
| Государственные налоги 2025 | 121 € | – | – | 2k € |
| Налоги на рабочую силу 2025 | 121 € | – | – | 0 € |
| Сотрудников 2025 | – | – | – | – |
| Оборот 2024 | 0 € | 0 € | 0 € | 0 € |
| Государственные налоги 2024 | – | – | 395 € | 330 € |
| Налоги на рабочую силу 2024 | – | – | 399 € | 330 € |
| Сотрудников 2024 | – | 1 | – | – |
- Serving as an authorized representative for medical and pharmaceutical enterprises, advocating for the collective interests of patients across EU member states, and of EU and non-EU manufacturers, and championing the propagation of EU culture and policies across the globe. - Facilitating the provision of EU Services for medicines, medical devices, in-vitro diagnostic medical devices, supplements and cosmetics, veterinary medicinal products and other industrial products to EU and non-EU manufacturers, including preclinical and clinical research support, marketing authorization registration, CE Mark certification issuance, import-export operations, warehousing, distribution, tendering processes, and the establishment of an extensive Agency & Partner Network. - Implementing Post-Market Surveillance and Pharmacovigilance, maintaining a vigilant and responsive system, and fostering close collaboration with governmental bodies and Health Agencies in the respective localities.